問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
鄭立廷
下載
2025-10-01 - 2035-01-20
Condition/Disease
DFS as assessed by the trial administrator. DFS is defined as the time elapsed from randomization until tumor recurrence or death from any cause (whichever occurs earlier).
Test Drug
Imfinzi® KEYTRUDA® OPDIVO Tecentriq® Zongertinib (BI 1810631)
Participate Sites6Sites
Recruiting6Sites
2025-09-01 - 2035-12-31
Non-small Cell Lung Cancer
Tablets; Subcutaneous injections
2022-01-01 - 2031-02-27
Participate Sites8Sites
Recruiting8Sites
2023-09-01 - 2029-12-31
Participate Sites13Sites
Recruiting13Sites
2024-01-01 - 2030-06-30
Participate Sites10Sites
Recruiting10Sites
2025-06-01 - 2029-06-30
Participate Sites7Sites
Recruiting7Sites
2025-03-01 - 2028-03-31
Participate Sites9Sites
Recruiting9Sites
2023-12-24 - 2027-03-01
Participate Sites5Sites
Recruiting5Sites
2024-12-01 - 2027-12-31
2025-04-01 - 2027-12-31
全部
